So far, there are still no effective and specific anti-dengue drugs. Dengue virus (DENV) nonstructural protein 1 (NS1) plays an important role in hemorrhagic pathogenesis. We have identified an anti-NS1 monoclonal antibody, which can protect against four serotypes of DENV infection and prevent the risk of ADE. Moreover, humanization of antibody makes this product forward to clinical treatment.

1.As compared to general anti-viral drugs, antibody therapy is more specific. 
2.As compared to neutralizing antibody against viral envelope protein, this antibody targets DENV NS1 and prevents the risk of side effect of ADE.  
3.By antibody humanization and optimization, treatment with this antibody can reduce the antigen rejection. 
4.This antibody does not recognize human cells or cause auto-reaction.

More than one third of the world’s population is now at risk of dengue. Although there is an approved dengue vaccine now, it may cause safety concern, which limits the usage and market. This technique prevents the risk of disease deterioration, which can act as a first-line treatment and compensate the limitation of dengue vaccine. It can apply for global disease prevention and public healthcare.